Prognosis

J&J Forges $1 Billion Pact With U.S. for Covid-19 Vaccine Supply

Experimental vaccine offers one-shot alternative to others
One in a series of deals by the government to speed delivery

Watch: Several pharmaceutical firms have been snapping up deals with governments to be the first in line to get the coronavirus vaccine once it comes out. (Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Riley Griffin

August 5, 2020 at 12:47 PM UTC

Updated on

August 5, 2020 at 2:36 PM UTC

This article is for subscribers only.

Johnson & Johnson said it has agreed to supply 100 million doses of its experimental Covid-19 vaccine to the U.S. for more than $1 billion, the latest in a string of such pacts between the government and pharmaceutical companies.

Under the agreement, J&J will manufacture and deliver its SARS-CoV-2 investigational vaccine in the U.S., according to a statement by the health-care giant on Wednesday. The J&J vaccine is expected to go into late-stage trials in September.